Skip to main content
Fig. 3 | Infectious Diseases of Poverty

Fig. 3

From: A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model

Fig. 3

Protective efficacy of the vaccines in guinea pigs when administered by different routes. Protective efficacy of vaccines as evaluated by the effectiveness of vaccination (a), index of infection (b) and isolation rate of Brucella (c) from the tissues of control and experimental groups of guinea pigs on day 30 after challenging with the virulent strain of B. melitensis 16 M. Animals were vaccinated with the vector vaccine by prime-boost conjunctival (c.), intranasal (i.n.), sublingual (s.l.) at interval of 21 days, and with B. melitensis Rev.1 by single subcutaneous (s.c.) vaccination. Guinea pigs in negative control group were injected with PBS. The challenge of animals was performed with B. melitensis 16 M at a dose of 20 CFU/animal using s.c. route. Bacteriological evaluation was assessed by the index of infection in animals (the arithmetic mean ± standard error was given for each group; the number of organs and lymph nodes from which Brucella was isolated for each animal) and by counting Brucella colonies in tissues, where data is expressed as log10 CFU/g. Statistical difference between groups was indicated with asterisks and statistical analysis for (B) was performed using a one-way ANOVA followed by Dunnett's multiple comparisons test and (*, P < 0.01; **, P < 0.002) and for c two-way ANOVA, Tukey’s multiple comparisons test (*P = 0.04–0.01; **P = 0.009–0.001; ***P = 0.0004–0.0002, ****P < 0.0001)

Back to article page